...
首页> 外文期刊>Stem cells translational medicine. >Comparison of Different Cytokine Conditions Reveals Resveratrol as a New Molecule for Ex Vivo Cultivation of Cord Blood-Derived Hematopoietic Stem Cells
【24h】

Comparison of Different Cytokine Conditions Reveals Resveratrol as a New Molecule for Ex Vivo Cultivation of Cord Blood-Derived Hematopoietic Stem Cells

机译:不同细胞因子条件的比较显示白藜芦醇作为脐带血来源的造血干细胞在体外培养的新分子

获取原文

摘要

Human cord blood (CB)-derived hematopoietic stem cells (HSCs) are an interesting source for HSC transplantation. However, the number of collected CB-HSCs is often too low for one transplantation; therefore, ex vivo expansion of CB-HSCs is desirable. Current expansion protocols are based on the use of cytokine combinations, including insulin-like growth factor-binding protein 2 (IGFBP2) and angiopoietin-like proteins, or combinations with "small molecules" such as stemregenin-1. The aim of our project was to compare the potential of different CB-HSC expansion strategies side-by-side by phenotypical analysis in vitro and serial engraftment properties in NOD/SCID/IL2rg-/- (NSG) immunodeficient mice. We further identified resveratrol, a naturally occurring polyphenol, as a new, alternative small molecule combined with cytokines to facilitate serum-free ex vivo expansion of human CB-HSCs. The cultivation in resveratrol preserved the CB-HSC phenotype in vitro most efficiently and was [~]2 times more potent than commonly used cytokine conditions (including stem cell factor, thrombopoietin, Fms-related tyrosine kinase 3 ligand, interleukin-6) and the recently established serum-free culture, including IGFBP2 and angiopoietin-like 5. Serial transplantation studies further confirmed resveratrol to support robust multilineage engraftment in primary and secondary NSG recipients. Therefore, our work proposes resveratrol as a new small molecule for improved ex vivo culture and modification of human HSCs based on an efficient ex vivo propagation of the HSC fate. SignificanceHuman cord blood (CB)-derived hematopoietic stem cells (HSCs) are an important source for HSC transplantations but restricted in their usage because of their low numbers. In gene therapy, modifications of HSCs relies on their ex vivo modification without losing their stemness properties. Therefore, ex vivo cultivation and expansion of CB-HSCs is important for their effective application in HSC transplantation and gene therapy. Several promising protocols for serum-free cultivation of HSCs using different combinations of cytokines or so-called small molecules are described. A direct comparison was performed of three described serum-free cytokine conditions, demonstrating that the natural occurring polyphenol resveratrol is able to support ex vivo cultivation of CB-HSCs. The results show that resveratrol is an additional candidate for improving ex vivo cultures of HSCs for transplantation and gene therapeutic applications in the future.
机译:人脐带血(CB)来源的造血干细胞(HSC)是HSC移植的有趣来源。但是,对于一次移植来说,收集到的CB-HSC的数量通常太少。因此,离体扩增CB-HSC是理想的。当前的扩展方案是基于细胞因子组合的使用,包括胰岛素样生长因子结合蛋白2(IGFBP2)和血管生成素样蛋白,或与“小分子”的组合,如stemregenin-1。我们项目的目的是通过表型分析和NOD / SCID / IL2rg-/-(-NSG)免疫缺陷小鼠的系列移植特性,并排比较不同CB-HSC扩展策略的潜力。我们进一步确定了白藜芦醇,一种天然存在的多酚,是与细胞因子结合的新的替代性小分子,可促进人CB-HSC的无血清离体扩增。白藜芦醇的培养在体外最有效地保留了CB-HSC表型,效力比常用细胞因子条件(包括干细胞因子,血小板生成素,Fms相关酪氨酸激酶3配体,白介素6)强[〜] 2倍。最近建立的无血清培养物,包括IGFBP2和血管生成素样5。串行移植研究进一步证实白藜芦醇可支持主要和次要NSG接受者的稳健多系移植。因此,我们的工作提出白藜芦醇作为一种新的小分子,用于基于HSC命运的有效离体繁殖,改善离体培养和人类HSC的修饰。意义人脐血(CB)来源的造血干细胞(HSC)是HSC移植的重要来源,但由于其数量少而受到限制。在基因治疗中,HSC的修饰依赖于其离体修饰而不会失去其干性。因此,CB-HSC的离体培养和扩增对其在HSC移植和基因治疗中的有效应用很重要。描述了使用细胞因子或所谓的小分子的不同组合进行HSC的无血清培养的几种有希望的方案。对三种描述的无血清细胞因子条件进行了直接比较,表明天然存在的多酚白藜芦醇能够支持离体培养CB-HSC。结果表明,白藜芦醇是将来为移植和基因治疗应用改善HSC的离体培养的另一候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号